178 related articles for article (PubMed ID: 27003305)
1. Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses.
Rohde U; Sonne DP; Christensen M; Hansen M; Brønden A; Toräng S; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2016 May; 101(5):2076-83. PubMed ID: 27003305
[TBL] [Abstract][Full Text] [Related]
2. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
Keller J; Trautmann ME; Haber H; Tham LS; Hunt T; Mace K; Linnebjerg H
Regul Pept; 2012 Nov; 179(1-3):77-83. PubMed ID: 22960288
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
Brønden A; Albér A; Rohde U; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2017 Nov; 102(11):4153-4162. PubMed ID: 28938439
[TBL] [Abstract][Full Text] [Related]
4. Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.
Shaddinger BC; Young MA; Billiard J; Collins DA; Hussaini A; Nino A
J Clin Pharmacol; 2017 Oct; 57(10):1322-1329. PubMed ID: 28543352
[TBL] [Abstract][Full Text] [Related]
5. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Rohde U
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
[TBL] [Abstract][Full Text] [Related]
6. The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.
Brønden A; Albér A; Rohde U; Gasbjerg LS; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2018 Feb; 20(2):362-369. PubMed ID: 28786523
[TBL] [Abstract][Full Text] [Related]
7. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs.
Rehfeld JF; Knop FK; Asmar A; Madsbad S; Holst JJ; Asmar M
Scand J Gastroenterol; 2018 Dec; 53(12):1429-1432. PubMed ID: 30449207
[TBL] [Abstract][Full Text] [Related]
9. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2016 Jun; 18(6):571-80. PubMed ID: 26888164
[TBL] [Abstract][Full Text] [Related]
10. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
Sonne DP; Hare KJ; Martens P; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G413-9. PubMed ID: 23275610
[TBL] [Abstract][Full Text] [Related]
11. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
12. Entero-Pancreatic Hormone Secretion, Gastric Emptying, and Glucose Absorption After Frequently Sampled Meal Tests.
Veedfald S; Rehfeld JF; van Hall G; Svendsen LB; Holst JJ
J Clin Endocrinol Metab; 2022 Jan; 107(1):e188-e204. PubMed ID: 34479362
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study.
Hansen NL; Brønden A; Nexøe-Larsen CC; Christensen AS; Sonne DP; Rehfeld JF; Wever Albretchsen NJ; Hartmann B; Vilsbøll T; Holst JJ; Knop FK
Clin Transl Gastroenterol; 2020 Dec; 11(12):e00257. PubMed ID: 33512799
[TBL] [Abstract][Full Text] [Related]
14. Effect of insulin on basal and cholecystokinin-stimulated gallbladder motility in humans.
Gielkens HA; Lam WF; Coenraad M; Frölich M; van Oostayen JA; Lamers CB; Masclee AA
J Hepatol; 1998 Apr; 28(4):595-602. PubMed ID: 9566827
[TBL] [Abstract][Full Text] [Related]
15. The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes.
Rohde U; Federspiel CA; Vilmann P; Langholz E; Friis SU; Krakauer M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2017 Feb; 19(2):189-199. PubMed ID: 27696668
[TBL] [Abstract][Full Text] [Related]
16. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides.
Rehfeld JF
Acta Physiol (Oxf); 2011 Apr; 201(4):405-11. PubMed ID: 21392266
[TBL] [Abstract][Full Text] [Related]
17. [Study on CCK-induced gallbladder emptying with real-time ultrasonography].
Wang Z; Wu J; Miao X
Zhonghua Nei Ke Za Zhi; 1995 Jun; 34(6):385-7. PubMed ID: 8582185
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous fat on cholecystokinin secretion and gallbladder motility in man.
de Boer SY; Masclee AA; Jebbink MC; Schipper J; Jansen JB; Lamers CB
JPEN J Parenter Enteral Nutr; 1992; 16(1):16-9. PubMed ID: 1738213
[TBL] [Abstract][Full Text] [Related]
19. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
Ellrichmann M; Kapelle M; Ritter PR; Holst JJ; Herzig KH; Schmidt WE; Schmitz F; Meier JJ
J Clin Endocrinol Metab; 2008 Oct; 93(10):3995-8. PubMed ID: 18647814
[TBL] [Abstract][Full Text] [Related]
20. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility.
MacIntosh CG; Andrews JM; Jones KL; Wishart JM; Morris HA; Jansen JB; Morley JE; Horowitz M; Chapman IM
Am J Clin Nutr; 1999 May; 69(5):999-1006. PubMed ID: 10232642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
